01. Doctor Overview
Dr. Bonomi is board certified in internal medicine and medical oncology. His primary area of interest is within the field of thoracic and cardiothoracic oncology, with specialties in lung cancer and mesothelioma. The majority of Dr. Bonomi’s research interest is in the field of lung cancer treatment and detection. He also has experience in treating mesothelioma cancer.
He is also a professor within the Rush Medical College at Rush University. With more than 20 years of experience, Dr. Bonomi brings his clinical expertise with him into the classroom. Dr. Bonomi has also authored or co-authored over 150 publications, primarily in the field of small-cell lung cancer detection and survival-rate improvements, sharing his vast knowledge with others in the field.
02. Fast Facts
Doctor Fast Facts
Main Specialty: Medical Oncology
Other Interests & Specialties: Mesothelioma, lung cancer, hematologic oncology, general oncology, thoracic cancer and internal medicine.
Certifications, Awards & Accolades: American Board of Internal Medicine Certification in Internal Medicine, American Board of Internal Medicine Certification in Medical Oncology, America’s Top Doctor, America’s Top Doctor for Cancer
Education & Experience:
- Medical Degree from University of Illinois College of Medicine
- Residency in Internal Medicine at Geisinger Medical Center
- Fellowship in Medical Oncology at Rush University Medical Center
The Effect of Necitumumab in Combination with Gemcitabine plus Cisplatin on Tolerability and on Quality of Life: Results from the Phase 3 SQUIRE Trial. Journal of Thoracic Oncology. June 2016;11(6):808-818. doi: 10.1016/j.jtho.2016.03.002
Clinician Perspectives on Current Issues in Lung Cancer Drug Development. Journal of Thoracic Oncology. September 2016;11(9):1387-1396. doi: 10.1016/j.jtho.2016.05.009
Implications of key trials in advanced nonsmall cell lung cancer. Cancer. March 2010;116(5):1155-1164. doi: 10.1002/cncr.24815
Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. Journal of Clinical Oncology. July 2009;27(20):3284-3289. doi: 10.1200/JCO.2008.20.8181